KORU Medical Posts Strong Q2 2026 Growth but Shifts U.S. Oncology Strategy — KORU Medical Systems, Inc.

Event summary

Q2 2026 revenue grew 18% YoY to $12.0M, with gross margin expanding to 65.1%
Net income improved 222% YoY to $0.25M, marking a significant profitability turnaround
Acquired connected monitoring technology asset for potential platform enhancement
Withdrew Phesgo® 510(k) application and shifted U.S. oncology focus to higher-volume molecules
Updated FY 2026 guidance: revenue $47.5M-$48.5M (15-18% growth), gross margin 62-64%

The big picture

KORU Medical's strong Q2 performance highlights its ability to drive profitable growth in the subcutaneous drug delivery market. The strategic shift away from Phesgo® reflects broader industry trends toward higher-volume molecules and connected health technologies, positioning KORU for long-term value creation despite near-term execution challenges.

What we're watching

Technology Integration: How the newly acquired connected monitoring asset will enhance KORU's platform and differentiate its value proposition.
Market Strategy Shift: Whether focusing on alternative higher-volume molecules can successfully offset the withdrawal from Phesgo® in the U.S. oncology market.
International Growth: The pace at which KORU can navigate regional launch dynamics and capture delayed business in European markets converting to pre-filled syringes.